Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 5 ans
Étude MX93795 : étude de phase 2 randomisée, comparant l’efficacité et la tolérance d’une thérapie guidée par profilage génomique, thérapie ciblée ou immunothérapie anticancéreuse, avec celles d’une chimiothérapie à base de platine chez des patients ayant un cancer primitif inconnu traité par 3 cures de doublet de chimiothérapie d’induction à base de platine.
Les cellules du corps subissent parfois des changements qui rendent leur mode de croissance ou leur comportement anormal. Dans certains cas, les cellules modifiées engendrent un cancer ou une tumeur. ...
Country
France
organs
Cancer de primitif inconnu (CAPI)
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
The Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), in Moderate-to-Severe Chronic Plaque Psoriasis
Primary Efficacy Objective: To assess the efficacy of tildrakizumab (SCH-900222/MK-3222) (hereafter referred to as MK-3222) compared to placebo in the treatment of moderate-to-severe chronic plaque ps...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 6 ans
Étude MK-3475-170/KEYNOTE-170 : étude de phase 2 ; évaluant l’efficacité du pembrolizumab (MK-3475), chez des patients ayant un lymphome médiastinal primitif à grandes cellules b en rechute ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
MK-3475-170/KEYNOTE-170 : Etude de phase II portant sur le pembrolizumab (MK-3475) chez des patients ayant un lymphome médiastinal primitif à grandes cellules B en rechute ou réfractaire.
Country
France
organs
Lymphomes non hodgkinien
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Limited
Update Il y a 4 ans
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
To determine the anti-tumor effectiveness of oral suberoylanilide hydroxamic acid (SAHA) as measured by overall objective response rate (ORR) in patients with relapsed DLBCL (de novo or transformed).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck KGaA
Update Il y a 4 ans
A clinical study, carried out in different centers and using a placebo, to assess the effect of a medicinal product, containing sapropterin as the active substance, on mental abilities in young adults suffering from phenylketonuria, a genetic disease in which an enzyme defect leads to accumulation of a waste product (phenylketone) which can be detected in urine
The purpose of this pilot trial is to assess the effect of sapropterin on the cognitive abilities of young adults with phenylketonuria (PKU).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
In postmenopausal women with osteoporosis: To estimate the effect of treatment with MK-0822 50 mg once weekly (OW) on volumetric trabecular bone mineral density (vBMD) at the lumbar spine (assessed ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck
Update Il y a 4 ans
CERTO : Essai de phase 2 randomisé comparant l’efficacité du cétuximab à une chimiothérapie à base de platine associée ou non à 2 doses de cilengitide, en traitement de première ligne, chez des patients ayant un cancer du poumon non à petites cellules avancé. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité du cilengitide, en association avec du cétuximab et une chimiothérapie à base de platine, en comparaison avec une association thérapeutique comprenan...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme OÜ
Update Il y a 4 ans
A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Essential Hypertension
To evaluate the antihypertensive efficacy (as assessed by change in mean trough SiSBP) after 4 weeks of treatment with losartan/HCTZ combination therapy in comparison with losartan monotherapy in pedi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicenter 16 Week Study to Assess the Effect of Vitamin D3 8400 IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Over 70 Years Old
To compare change in mediolateral body sway (measured with eyes open using the AccuSwayPLUS platform) following administration of vitamin D3 8400 IU once-weekly for 16 weeks to that following administ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude KEYNOTE-756 : étude de phase 3, randomisée, en double aveugle, évaluant le pembrolizumab par rapport à un placebo en associaton avec une chimiothérapie et un traitement endocrine en adjuvant, chez des patients ayant un cancer du sein de stade précoce
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estro...
Country
France
organs
Sein
Specialty
Chimiothérapie
,
Hormonothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
1
2
3
4
5
6
7
8
9
10
Next